Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2015

View Archived Issues

Study of GABA-A receptor signaling in Down syndrome model yields potential treatment strategy

TaiGen initiates phase I/II trial of burixafor in AML

Discovery of a bacterial RNR-targeting antibiotic to combat resistance

Lycera enters clinic with first program, LYC-30937 for IBD

Advanced Proteome Therapeutics reports findings on APC-191 in tumor metastasis

Tamir Biotechnology updates development progress of TMR-004 for Ebola

Novo Nordisk presents pipeline events of first quarter 2015

AstraZeneca discloses novel PI3Kalpha/delta inhibitior

BioLineRx's phase II study of BL-8040 for AML enters expansion stage

Shire and Foundation Fighting Blindness collaborate on autosomal dominant retinitis pigmentosa

New efficacy data presented for the antibody-drug conjugate ASN-004

Isis licenses ISIS-FXIRx to Bayer for prevention of thrombosis

Eisai develops new TLR7 and TLR8 antagonists

GlaxoSmithKline patents PERK inhibitors

Dana-Farber Cancer Institute discloses CDK7 inhibitors

Syros Pharmaceuticals and Paraza Pharma patent CDK7 inhibitors

The Blanchette Rockefeller Neurosciences Institute patents PKC-epsilon activators

Generon's F-652 cleared to enter phase II for acute graft-versus-host disease

Baxter submits European MAA for MM-398 for pancreatic cancer

European orphan drug designation for Makindus' MI-100 in Stargardt's disease

Dosing begins in Nigerian bridging study of Lodonal for HIV/AIDS

New phase II trial investigates Luminate for non-proliferative diabetic retinopathy

AEOL-10150 doubles survival in primate model of radiation-induced lung injury

CytRx offers interim reports from phase Ib aldoxorubicin combination studies

ARVO news: First-in-human clinical study of RetinoStat in wet AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...